Pixium Vision’s Research Partner, Stanford University, to Present Results of PRIMA: Wireless Subretinal Implant

Regulatory News :

Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced that its research partner, Stanford University’s Hansen Experimental Physics Laboratory, will present today during the invited session on advances and challenges in visual prosthetics at the 7^th International IEEE EMBS Neural Engineering conference in Montpellier, France.

The presentation entitled "Photovoltaic restoration of high visual acuity in rats with retinal degeneration” details the pre-clinical results of PRIMA, wireless subretinal photovoltaic implant, developed by Stanford University to convert pulsed near infra-red light into bi-phasic pulses of current to stimulate the nearby inner retinal neurons.

Professor Daniel Palanker from the Department of Ophthalmology and Hansen Experimental Physics Laboratory at Stanford University and academic partner of Pixium Vision said "The pre-clinical results of the wireless subretinal photovoltaic arrays we have developed are very encouraging. They demonstrate that network-mediated retinal stimulation preserves many features of natural vision. PRIMA promises to provide visual acuity exceeding the threshold of legal blindness in human patients. We continue to work on implants with even smaller pixels to further improve visual acuity.”

In-vitro and in-vivo experiments demonstrate that the network-mediated retinal stimulation preserves many features of natural vision, such as flicker fusion, adaptation to static images, and most importantly, high spatial resolution. The implants restored visual acuity to half of the normal level in rats with retinal degeneration at stimulation thresholds far below the ocular safety limits. Importantly, Optical Coherence Tomography (OCT) demonstrated good preservation of the inner retina one year after implantation.

The presentation will take place 13:45 in Pasteur Auditorium
during the Invited Session WeCT1.

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision’s VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS^® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. The approval of IRIS^® is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX
IRIS^® is a trademark of Pixium-Vision SA

About IEEE (Institute of Electrical and Electronics Engineers)

IEEE is the world's largest professional association dedicated to advancing technological innovation and excellence for the benefit of humanity. IEEE and its members inspire a global community through IEEE's highly cited publications, conferences, technology standards, and professional and educational activities.

About EMBS (Engineering in Medicine & Biology Society)

Engineering in Medicine and Biology Society (EMBS) is the world's largest international society of biomedical engineers. The organization's 9,100 members reside in some 97 countries around the world. EMBS provides its members with access to the people, practices, information, ideas and opinions that are shaping one of the fastest growing fields in science.

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).